Harvard Bioscience Inc (HBIO)vsResMed Inc (RMD)
HBIO
Harvard Bioscience Inc
$5.13
-3.93%
HEALTHCARE · Cap: $235.92M
RMD
ResMed Inc
$226.31
-0.82%
HEALTHCARE · Cap: $33.31B
Smart Verdict
WallStSmart Research — data-driven comparison
ResMed Inc generates 6137% more annual revenue ($5.40B vs $86.55M). RMD leads profitability with a 27.5% profit margin vs -65.5%. HBIO appears more attractively valued with a PEG of 1.31. RMD earns a higher WallStSmart Score of 70/100 (B).
HBIO
Avoid30
out of 100
Grade: F
RMD
Strong Buy70
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for HBIO.
Margin of Safety
+14.4%
Fair Value
$303.30
Current Price
$226.31
$76.99 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Strong operational efficiency at 35.2%
Safe zone — low bankruptcy risk
Every $100 of equity generates 26 in profit
Keeps 28 of every $100 in revenue as profit
Areas to Watch
Smaller company, higher risk/reward
ROE of -147.1% — below average capital efficiency
Revenue declined 3.3%
Earnings declined 80.3%
No major concerns identified
Comparative Analysis Report
WallStSmart ResearchBull Case : HBIO
The strongest argument for HBIO centers on Price/Book. PEG of 1.31 suggests the stock is reasonably priced for its growth.
Bull Case : RMD
The strongest argument for RMD centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 27.5% and operating margin at 35.2%. Revenue growth of 11.0% demonstrates continued momentum.
Bear Case : HBIO
The primary concerns for HBIO are Market Cap, Return on Equity, Revenue Growth.
Bear Case : RMD
No major red flags identified for RMD, but monitor valuation.
Key Dynamics to Monitor
HBIO profiles as a turnaround stock while RMD is a mature play — different risk/reward profiles.
HBIO carries more volatility with a beta of 1.45 — expect wider price swings.
RMD is growing revenue faster at 11.0% — sustainability is the question.
RMD generates stronger free cash flow (311M), providing more financial flexibility.
Bottom Line
RMD scores higher overall (70/100 vs 30/100), backed by strong 27.5% margins and 11.0% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Harvard Bioscience Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enable fundamental research, discovery, and preclinical testing for drug development. The company is headquartered in Holliston, Massachusetts.
ResMed Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
ResMed is a San Diego, California-based medical equipment company. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea (such as CPAP devices and masks), chronic obstructive pulmonary disease (COPD), and other respiratory conditions.
Visit Website →Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?